## 1 Amendments to the Claims:

2 This listing of claims will replace all prior versions, and listings of claims in the application:

## 3 <u>Listing of Claims:</u>

- (Currently amended) A timed-release compression-coated solid 1. 4 composition for oral administration to a subject, said composition comprising: 5 a) a core tablet comprising a drug and a freely erodible filler, wherein said core 6 tablet erodes approximately 40% to approximately 90% in the digestive tract of said subject .but 7 still retains the shape of the compression-coated solid composition to a certain extent although it 8 9 is being eroded; b) an outer layer, wherein said outer layer is made from a hydrogel-forming 10 polymer substance, and a hydrophilic base, wherein said hydrogel-forming polymer substance 11 has a viscosity-average molecular weight of 2,000,000 or higher and/or a viscosity in an aqueous 12 1% solution (25° C) of 1,000 cp or higher, and said hydrophilic base having solubility such that 13 the amount of water needed to dissolve 1g of said hydrophilic base is 5 mL or less; and 14 15 c) wherein the outer layer optionally contains another drug and the outer layer essentially does not contain the same drug as the core tablet drug. 16
  - 2. (Canceled)

1

- 3. (Original) The timed-release compression-coated solid composition for oral administration according to claim 1, wherein there is approximately 75 wt% or less of said drug, approximately 5 to approximately 80 wt% freely erodible filler, approximately 10 to approximately 95 wt% hydrogel-forming polymer substance, and approximately 5 to approximately 80 wt% hydrophilic base.
- 4. (Original) The timed-release compression-coated solid composition for oral administration according to claim 1, wherein the freely erodible filler is 1 or 2 or more selected from the group consisting of malic acid, citric acid, tartaric acid, polyethylene glycol, sucrose, and lactulose.

5. The timed-release compression-coated solid composition (Original) 1 for oral administration according to claim 1, wherein the freely erodible filler is 1 or 2 or more 2 selected from the group consisting of malic acid, citric acid and tartaric acid. 3 6. (Original) The timed-release compression-coated solid composition 1 2 for oral administration according to claim 1, wherein the freely erodible filler for a basic drug is 3 1 or 2 or more selected from the group consisting of malic acid, citric acid and tartaric acid. 7. The timed-release compression-coated solid composition 1 (Original) 2 for oral administration according to claim 1, wherein the freely erodible filler for an acidic or neutral drug is 1 or 2 or more selected from the group consisting of polyethylene glycol, sucrose 3 4 or lactulose. 8. The timed-release compression-coated solid composition 1 (Original) 2 for oral administration according to claim 1, wherein the hydrogel-forming polymer substance contains at least one type of polyethylene oxide. 3 9. 1 (Canceled) The timed-release compression-coated solid composition 1 10. (Original) for oral administration according to claim 1, wherein the core tablet contains hydrogel-forming 2 3 polymer substance. The timed-release compression-coated solid composition 1 11. (Original) 2 for oral administration according to claim 1, wherein the hydrophilic base is 1 or 2 or more 3 having solubility such that the amount of water needed to dissolve 1 g base is 5 mL or less. 1 12. The timed-release compression-coated solid composition (Original) for oral administration according to claim 11, wherein the hydrophilic base is 1 or 2 or more 2 selected from the group consisting of polyethylene glycol, sucrose, and lactulose. 3 1 13. The timed-release compression-coated solid composition (Original) 2 for oral administration according to claim 1, wherein the hydrogel-forming polymer substance is

- at least 1 type of polyethylene oxide and further contains red ferric oxide and/or yellow ferric
  oxide.
- 1 14. (Original) The timed-release compression-coated solid composition
- 2 for oral administration according to claim 1, wherein a drug is brought to be effectively released
- 3 or absorbed in the lower digestive tract.
- 1 15. (Original) The timed-release compression-coated solid composition
- 2 for oral administration according to claim 1, wherein a drug is brought to be effective for
- 3 chronopharmacotherapy.
- 1 16. (Original) The timed-release compression-coated solid composition
- 2 for oral administration according to claim 1, wherein a drug is metabolized by cytochrome P-
- 3 450.
- 1 17. (Original) The timed-release compression-coated solid composition
- 2 for oral administration according to claim 1, wherein a drug has the effect of inhibiting
- 3 metabolism by cytochrome P-450.
- 1 18. (Original) The timed-release compression-coated solid composition
- 2 for oral administration according to claim 16, wherein the drug is metabolized by CYP3A4.
- 1 19. (Original) The timed-release compression-coated solid composition
- 2 for oral administration according to claim 17, wherein the drug has the effect of inhibiting
- 3 metabolism by CYP3A4.
- 1 20. (Original) The timed-release compression-coated solid composition
- 2 for oral administration according to claim 1, wherein the drug is 4'-[(2-methyl-1,4,5,6-
- 3 tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzanilide or its salt.
- 1 21. (Original) A method of timed release of a drug, whereby the
- 2 composition in claim 1 is orally administered.

1	22. (Original) A method for alleviating undesirable drug interaction
2	between a drug and other drugs used concomitantly that employ the same route for drug
3	absorption, distribution, metabolism or excretion in vivo in humans, whereby the composition in
4	claim 1 is orally administered.
1	23. (Original) A method of alleviating undesirable drug interaction with
2	between a drug having the effect of inhibiting drug metabolism in vivo in humans and another
3	drug according to claim 20 used concomitantly, whereby the composition in claim 1 is used.
1	24. (Original) In a hydrogel-forming compression-coated solid
2	pharmaceutical preparation comprising: a core tablet containing drug and outer layer made from
3	hydrogel-forming polymer substance and hydrophilic base, the improvement which comprises a
4.	timed-release compression-coated solid composition according to claim 1.
1	25. (Original) In a hydrogel-forming compression-coated solid
2	pharmaceutical preparation comprising:
3	a core tablet containing drug and outer layer made from hydrogel-forming polymer
4	substance and hydrophilic base, the improvement which comprises a timed-release compression
5	coated solid composition for oral administration, said composition comprising:
6	(1) a drug and freely erodible filler are mixed with the core tablet;
7	(2) the percentage erosion of the core tablet is approximately 40 to approximately 90%;
8	and
9	(3) the outer layer essentially does not contain the same drug as the above-mentioned
Δ	drug

19

- 26. (Original) The timed-release compression-coated solid composition for oral administration according to claim 25, wherein the drug is 4'-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzanilide or its salt.
- 1 27. (New) A timed-release compression-coated solid composition for oral 2 administration, to a subject, said composition comprising: a) a core tablet comprising a drug and a freely erodible filler, wherein said core 3 4 tablet erodes approximately 40% to approximately 90% in the digestive tract of said subject, 5 wherein percentage erosion is determined by a method: i) a compression-coated tablet is moistened for 3 hours in water at 37°C; 6 ii) the gelled part of the tablet is peeled off and the portion of the core tablet that 7 8 has not eroded is removed; iii) the core tablet is allowed to dry overnight in a dryer at 40° C and the weight is 9 10 determined; iv) the value obtained by subtracting dry weight from initial core tablet weight is 11 12 multiplied by 100; b) an outer layer, wherein said outer layer is made from a hydrogel-forming 13 polymer substance, and a hydrophilic base, wherein said hydrogel-forming polymer substance 14 15 has a viscosity-average molecular weight of 2,000,000 or higher and/or a viscosity in an aqueous 16 1% solution (25° C) of 1,000 cp or higher, and said hydrophilic base having solubility such that the amount of water needed to dissolve 1g of said hydrophilic base is 5mL or less; and 17 18 c) wherein the outer layer optionally contains another drug and the outer layer

essentially does not contain the same drug as the core tablet drug.